Skip to content
Medical Learning Institute Inc
Home
CME Activities
Educational Series
Featured Educational Series
Oncology Communications Skills
Shedding Light on T2D
The Evolution of HCT: NMPD Series
Vaccines in Older Adults Series
Accreditation
About MLI Accreditation
About Us
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Contact Us
Medical Learning Institute Inc
Home
CME Activities
Educational Series
Featured Educational Series
Oncology Communications Skills
Shedding Light on T2D
The Evolution of HCT: NMPD Series
Vaccines in Older Adults Series
Accreditation
About MLI Accreditation
About Us
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Contact Us
Pre-Assessment
Please enable JavaScript in your browser to complete this form.
Please enable JavaScript in your browser to complete this form.
Name
*
First
Last
Email
*
Location
*
Please choose
Delray Beach, FL
Missouri
South Dakota
Tennessee
Cape Cod, MA
Anaheim, CA
Virginia Beach, VA
Hershey, PA
Myrtle Beach, SC
Napa, CA
NPI Number
Which of the following best represents your profession?
MD/DO
NP
PA
Nurse
Other
If other, please specify:
What is your primary specialty?
Family Medicine
Internal Medicine
Neurology
Other
If other, please specify:
1. A 68-year-old retired teacher reports forgetting recent conversations and misplacing items more frequently. Her daughter notices she repeats questions often. Cognitive testing shows mild deficits in memory, but daily functioning is mostly intact. Based on guideline frameworks, what would be your clinical opinion?
A) Normal age-related cognitive changes
B) Mild cognitive impairment
C) Major neurocognitive disorder unrelated to AD
D) Moderate Alzheimer’s disease
with patients on
Please select the extent to which you feel confident in your answer.
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
Completely confident
Item #1 Completely confident
Fairly confident
Item #1 Fairly confident
Somewhat confident
Item #1 Somewhat confident
Slightly confident
Item #1 Slightly confident
Not confident
Item #1 Not confident
2. Which blood-based biomarker has been FDA-cleared for detecting amyloid pathology in patients with suspected AD?
A) Plasma pTau217/Beta-Amyloid 42
B) Plasma neurofilament light chain (NfL)
C) Plasma GFAP protein
D) Plasma GAD antibodies
Please select the extent to which you feel confident in your answer.
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
Completely confident
Item #1 Completely confident
Fairly confident
Item #1 Fairly confident
Somewhat confident
Item #1 Somewhat confident
Slightly confident
Item #1 Slightly confident
Not confident
Item #1 Not confident
3. A 70-year-old patient with MCI undergoes a blood-based biomarker test with a positive result. According to current guidelines, the next most appropriate step is:
A) Diagnose Alzheimer's disease and start treatment promptly
B) Repeat cognitive testing in 6 months without additional testing
C) Refer to a memory specialist
D) Confirm amyloid pathology with PET or CSF testing
Please select the extent to which you feel confident in your answer.
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
Completely confident
Item #1 Completely confident
Fairly confident
Item #1 Fairly confident
Somewhat confident
Item #1 Somewhat confident
Slightly confident
Item #1 Slightly confident
Not confident
Item #1 Not confident
4. In which of the following scenarios would blood-based biomarker testing for Alzheimer’s disease pathology be most appropriate to consider or refer for?
A) 40-year-old who is a smoker with sleep disturbances and a family history of Alzheimer's disease requesting testing to know their risk
B) 55-year-old with mild cognitive impairment confirmed on office-based screening and no reversible cause identified
C) 60-year-old reporting occasional forgetfulness but scoring normally on cognitive screening
D) 71-year-old with normal cognition who is anxious about developing Alzheimer’s disease due to family history
Please select the extent to which you feel confident in your answer.
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
Completely confident
Item #1 Completely confident
Fairly confident
Item #1 Fairly confident
Somewhat confident
Item #1 Somewhat confident
Slightly confident
Item #1 Slightly confident
Not confident
Item #1 Not confident
5. A negative blood-based biomarker result in a patient with Mild Cognitive Impairment generally indicates:
A) Inconclusive result requiring immediate PET
B) Need for amyloid targeting therapy initiation
C) Low likelihood of Alzheimer’s pathology
D) Retest to ensure the result is not a false negative
Please select the extent to which you feel confident in your answer.
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
Completely confident
Item #1 Completely confident
Fairly confident
Item #1 Fairly confident
Somewhat confident
Item #1 Somewhat confident
Slightly confident
Item #1 Slightly confident
Not confident
Item #1 Not confident
6. A 72-year-old patient has a positive blood-based biomarker test but atypical cognitive presentation. The primary care provider is unsure if AD pathology is the cause. According to current guidelines, the most appropriate action is:
A) Start amyloid targeting therapy immediately
B) Repeat the blood-based biomarker in 12 months
C) Confirm possible diagnosis with tau PET
D) Refer to a memory specialist for additional workup
Please select the extent to which you feel confident in your answer. (copy)
Completely confident
Fairly confident
Somewhat confident
Slightly confident
Not confident
Completely confident
Item #1 Completely confident
Fairly confident
Item #1 Fairly confident
Somewhat confident
Item #1 Somewhat confident
Slightly confident
Item #1 Slightly confident
Not confident
Item #1 Not confident
7. How confident are you in your ability to Appropriately evaluate and manage patients with early cognitive symptoms, including determining when and how to use blood-based biomarkers for Alzheimer’s disease.
A. Completely confident
B. Fairly confident
C. Somewhat confident
D. Slightly confident
E. Not confident
Submit
Scroll to Top